Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Arance

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialPaolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2023
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanomaSelina K Wong, Steven M Blum, Xiaopeng Sun, et al.
Medicine|February 1, 2018
Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization studySalvador Martín Algarra, Virtudes Soriano, Luis Fernández-Morales, et al.
Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Neuro-Oncology|July 1, 2024
Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)Iván Márquez-Rodas, Ana Álvarez, Ana Arance, et al.
The Lancet. Oncology|May 31, 2025
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Michal Kicinski, Caroline Dutriaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2025
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapyRachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
NEJM Evidence|September 24, 2024
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaPaolo A Ascierto, Mario Mandalà, Pier Francesco Ferrucci, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialPaolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2023
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanomaSelina K Wong, Steven M Blum, Xiaopeng Sun, et al.
Medicine|February 1, 2018
Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization studySalvador Martín Algarra, Virtudes Soriano, Luis Fernández-Morales, et al.
Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Neuro-Oncology|July 1, 2024
Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)Iván Márquez-Rodas, Ana Álvarez, Ana Arance, et al.
The Lancet. Oncology|May 31, 2025
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Michal Kicinski, Caroline Dutriaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2025
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapyRachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
NEJM Evidence|September 24, 2024
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaPaolo A Ascierto, Mario Mandalà, Pier Francesco Ferrucci, et al.
Pageof 10